S-nitrosoglutathione inhibits platelet activation and deposition in coronary artery saphenous vein grafts in vitro and in vivo

Heart

Volumn 80, Issue 2, 1998, Pages 146-150

  Salas, E ^a   Langford, E J ^b   Marrinan, M T ^b   Martin, J F ^c   Moncada, S ^c   De Belder, A J ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Coronary artery bypass surgery; Ischaemic heart disease; Platelet activation; S nitrosoglutathione

Indexed keywords

S NITROSOGLUTATHIONE;

ADULT; AGED; ARTERY GRAFT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; GRAFT FAILURE; GRAFT PATENCY; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; SAPHENOUS VEIN; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; VEIN GRAFT;

EID: 0031813784     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.80.2.146     Document Type: Article

References (23)

1. Chesebro JH, Clements IP, Fuster V, et al. A plateletinhibitor-drug trial in coronary-artery bypass operations. Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 1982;307:73-8.
2. RITA Trial Participants. Coronary angioplasty versus coronary artery bypass surgery: the randomised intervention treatment of angina (RTTA) trial. Lancet 1993;341: 73-80.
3. Grondin CM, Campeau L, Lesperance J, et al. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. Circulation 1984;70(suppl 1):I208-12.
4. Bourassa MG. Long-term vein graft patency. Curr Opin Cardiol 1994;9:685-91.
5. Goldman S, Copeland J, Moritz T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a veterans administration cooperative study. Circulation 1989;80: 1190-7.
6. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987;92:181-7.
7. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;ii:1057-8.
8. Yang Z, Stultz P, von Segesser L, et al. Different interactions of platelets with arterial and venous coronary bypass vessels. Lancet 1991;337:939-43.
9. Yang Z, von Segesser L, Bauer E, et al. Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res 1991;68:52-60.
10. Mehta J, Mehta P. Comparative effects of nitroprusside and nitroglycerin on platelet aggregation in patients with heart failure. J Cardiovasc Pharmacol 1980;2:25-33.
11. de Beider AJ, MacAllister R, Radomski MW, et al. Effects of S-nitrosoglutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res 1994;28:691-4.
12. Ramsey B, Radomski M, de Belder A, et al. Systemic effects of S-nitrosoglutathione in the human following intravenous infusion. Br J Clin Pharmacol 1995;40:101-2.
13. Langford EJ, Brown AS, Wainwright RJ, et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 1994;344:1458-60.
14. Miller DD, Rivera FJ, Garcia OJ, et al. Imaging of vascular injury with 99mTc-labelled monoclonal antiplatelet antibody S12. Preliminary experience in human percutaneous transluminal angioplasty. Circulation 1992;85:1354-63.
15. Palabrica TM, Furie BC, Konstam MA, et al. Thrombus imaging in a primate model with antibodies specific for an external membrane protein of activated platelets. Proc Natl Acad Sci USA 1989;86:1036-41.
16. 123I radiolabelling of monoclonal antibodies for in vivo procedures. Hybridoma 1986;5:265-75.
17. Luscher TF, Diederich D, Siebenmann R, et al. Difference between endothelium-dependent relaxation in arterial and venous coronary bypass grafts. N Engl J Med 1988;319: 462-7.
18. Yang Z, Diederich D, Schneider K, et al. Endothelium-derived relaxing factor and protection against contractions induced by histamine and serotonin in the human internal mammary artery and in the saphenous vein. Circulation 1989;80:1041-8.
19. Subramanian VA, Hernandez Y, Tack-Goldman K, et al. Prostacyclin production by internal mammary artery as a factor in coronary artery bypass grafts. Surgery 1986;100: 376-83.
20. Rinder CS, Bohnert J, Rinder HM, et al. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;75:388-93.
21. Bryan AJ, Angelini GD. The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr Opin Cardiol 1994;9:641-9.
22. Radomski MW, Rees DD, Dutra A, et al. S-nitrosoglutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 1992;107:745-9.
23. Langford EJ, Wainwright RJ, Martin JF. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler Thromb Vase Biol 1996;16:51-5.